Story · no single site
This piece is about a rule or market, not one plant.
B2Process
Daewon oral semaglutide tablet DW5324 beats Rybelsus exposure in two small studies
Daewon Pharmaceutical says its oral semaglutide candidate reached up to 3.14 times the exposure of Rybelsus in two crossover studies. The data are unpublished, and the company has not named a peptide supplier.
In one lineDaewon Pharmaceutical says its oral semaglutide candidate DW5324 reached 1.90 to 3.14 times the exposure of Rybelsus in two crossover studies of 18 and 19 people, presented at AAPS PharmSci 360.
